Xcelerate Inc. (XCRT) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
Market cap $8.20M is the value of all shares combined. Beta 0.72: the stock has moved about 28% less than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerXcelerate Inc. (XCRT) trades at $0.01888. Xcelerate Inc. focuses on acquiring and developing early-stage medical technologies for clinical settings. The company provides end-to-end medical technology development, aiming to accelerate innovation in healthcare. Market cap: $8.20M, Sector: Healthcare.
Price as of · Last analyzed: Mar 17, 2026Analyst Coverage for XCRT: XCRT does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
Xcelerate Inc. (XCRT) Healthcare & Pipeline Overview
Xcelerate Inc. operates within the medical care facilities sector, acquiring and developing early-stage medical technologies. The company provides end-to-end development services for controlled clinical environments, focusing on trialing, testing, and applying innovative medical solutions. With a small market capitalization, Xcelerate navigates a competitive landscape.
What Is the Investment Thesis for XCRT?
Xcelerate Inc. presents a high-risk, high-reward investment profile due to its focus on early-stage medical technologies. The company's negative P/E ratio of -20.90 and a negative profit margin of -22.8% indicate current financial challenges. A potential growth catalyst lies in the successful development and commercialization of acquired technologies. However, the company's small market capitalization of $8.20M and limited number of employees (12) suggest significant operational and financial constraints. Investors should carefully consider the risks associated with OTC-traded companies and the uncertainties inherent in early-stage technology development.
Based on FMP financials and quantitative analysis
XCRT Key Highlights
Market capitalization of $8.20M indicates a micro-cap company with high growth potential but also significant risk.
- Negative P/E ratio of -20.90 reflects current losses and the need for successful commercialization of technologies.
- Gross margin of 25.1% suggests potential for profitability if revenue scales effectively.
- Beta of 0.72 indicates lower volatility compared to the overall market, which may appeal to risk-averse investors.
- Profit margin of -22.8% highlights the company's current struggle to achieve profitability and the importance of cost management.
Who Are XCRT's Competitors?
XCRT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| BICX BioCorRx Inc. | $0.20 | 0.00% | $5.98M | — |
| GBCS Selectis Health, Inc. | $5.73 | 0.00% | $17.6M | — |
| AMS American Shared Hospital Services | $1.05 | +1.94% | $7.01M | 43 5-pillar |
| CCM Concord Medical Services Holdings Limited | $3.41 | -5.36% | $14.8M | — |
| DCGO DocGo Inc. | $0.17 | -2.22% | $17.0M | — |
| BTMD biote Corp. | $0.84 | -4.65% | $27.3M | 39 5-pillar |
| CCEL Cryo-Cell International, Inc. | $4.15 | -0.48% | $33.5M | 33 5-pillar |
| AIRS AirSculpt Technologies, Inc. | $0.65 | -8.87% | $48.4M | 33 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are XCRT's Key Strengths?
Focus on early-stage medical technology development.
- End-to-end service offering.
- Access to controlled clinical settings.
- Proprietary technology and patents.
What Are XCRT's Weaknesses?
Small market capitalization.
- Negative profitability metrics.
- Limited number of employees.
- Reliance on successful technology development and commercialization.
What Could Drive XCRT Stock Higher?
Successful completion of clinical trials for key technologies.
- Securing strategic partnerships with major hospital networks.
- Expansion of the company's patent portfolio.
- Increased adoption of Xcelerate's technologies in clinical settings.
What Are the Key Risks for XCRT?
Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Regulatory hurdles and delays in obtaining approvals.
- Competition from larger, more established companies.
- Financial constraints and funding challenges.
- Technological obsolescence and the need for continuous innovation.
What Are the Growth Opportunities for XCRT?
- Expansion into Telemedicine: The telemedicine market is projected to reach $460 billion by 2030, presenting a significant opportunity for Xcelerate to integrate its technologies into remote patient monitoring and virtual care solutions. This expansion would require strategic partnerships and adaptation of existing technologies for remote applications, potentially increasing revenue streams within the next 3-5 years.
- Strategic Partnerships with Hospitals: Collaborating with hospital networks to implement and test Xcelerate's technologies in real-world clinical settings can accelerate adoption and validation. Securing long-term contracts with hospitals can provide a stable revenue base and enhance the company's credibility. This initiative could yield substantial results within 2-3 years.
- Development of AI-Driven Diagnostics: Integrating artificial intelligence into diagnostic tools can improve accuracy and efficiency in clinical settings. The AI in healthcare market is expected to reach $95 billion by 2030. Xcelerate can leverage its existing technologies to develop AI-powered solutions, potentially attracting investment and increasing market share within 3-5 years.
- Focus on Geriatric Care Technologies: With the aging global population, there is a growing demand for technologies that improve geriatric care. Xcelerate can develop and market solutions tailored to the needs of elderly patients, such as remote monitoring devices and assistive technologies. This targeted approach can drive revenue growth within 2-4 years.
- Acquisition of Complementary Technologies: Acquiring companies with complementary technologies can expand Xcelerate's product portfolio and market reach. Strategic acquisitions can provide access to new markets, technologies, and expertise, accelerating growth and enhancing the company's competitive position. This inorganic growth strategy could yield significant benefits within 1-3 years.
What Are XCRT's Competitive Advantages?
- Proprietary Technology: Ownership of unique engineering designs and patents.
- End-to-End Development: Comprehensive service offering from concept to clinical application.
- Controlled Clinical Settings: Access to environments for testing and validation.
- Specialized Expertise: Focus on early-stage medical technology development.
What Does XCRT Do?
Xcelerate Inc., formerly known as Union Dental Holdings, Inc., was incorporated in 1996 and is based in Coral Springs, Florida. The company specializes in acquiring engineering designs and patents, which are then applied to early-stage medical technology companies. Xcelerate's core business model revolves around supplying these technologies to controlled clinical care settings, where they can be trialed, tested, and ultimately implemented. This end-to-end approach allows for a comprehensive and controlled development process, from initial concept to practical application. Xcelerate positions itself as a facilitator of medical technology advancement, focusing on bridging the gap between innovative ideas and real-world clinical use. While the company's headquarters are in Coral Springs, its original incorporation was in Mauldin, South Carolina, reflecting its historical evolution.
What Products and Services Does XCRT Offer?
- Acquires engineering designs and patents.
- Applies acquired technologies to early-stage medical companies.
- Supplies technologies to controlled clinical care settings.
- Facilitates trials and testing of new medical technologies.
- Provides end-to-end medical technology development services.
- Focuses on bridging the gap between innovation and clinical application.
How Does XCRT Make Money?
- Acquire promising engineering designs and patents.
- Develop and refine these technologies for clinical applications.
- Supply developed technologies to controlled clinical settings for testing and implementation.
- Generate revenue through licensing agreements and technology sales.
What Industry Does XCRT Operate In?
Xcelerate Inc. operates within the medical care facilities industry, which is characterized by rapid technological advancements and increasing demand for innovative healthcare solutions. The industry is highly competitive, with companies ranging from established medical device manufacturers to smaller, specialized technology developers. Xcelerate's focus on early-stage technologies positions it within a niche segment of the market, requiring effective navigation of regulatory hurdles and successful commercialization of its acquired assets. The company's success depends on its ability to identify and develop promising technologies that address unmet needs in clinical care settings.
Who Are XCRT's Key Customers?
- Early-stage medical technology companies.
- Controlled clinical care settings.
- Hospitals and medical facilities.
- Healthcare providers seeking innovative solutions.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● No filing on record
- ● No analyst coverage
How Xcelerate Inc. Is Valued
Xcelerate Inc. carries a market capitalization of $8.20M, placing it in the micro-cap category.
Company Profile
Xcelerate Inc. operates in the Medical - Care Facilities industry within the Healthcare sector. It is headquartered in Mauldin, US. The company is led by CEO Michael F. O'Shea. XCRT has traded publicly since 2001.
Key Financial Metrics
Return on equity for Xcelerate Inc. stands at 46.3%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -7.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.07 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -10.2%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Xcelerate Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
XCRT Financials
Bull Case vs Bear Case
Bull Case
- Focus on early-stage medical technology development.
- End-to-end service offering.
- Access to controlled clinical settings.
- Proprietary technology and patents.
Bear Case
- Small market capitalization.
- Negative profitability metrics.
- Limited number of employees.
- Reliance on successful technology development and commercialization.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
XCRT Latest News
No recent news available for XCRT.
XCRT Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for XCRT.
Price Targets
Wall Street price target analysis for XCRT.
XCRT MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for XCRT; grades run from A+ (80-100) to F (below 30).
Leadership: Michael F. O'Shea
CEO
Michael F. O'Shea serves as the CEO of Xcelerate Inc., overseeing the company's strategic direction and operations. His background includes experience in managing and developing early-stage companies, with a focus on technology and healthcare sectors. O'Shea's expertise lies in identifying and nurturing innovative technologies, guiding them through the development process, and bringing them to market. He is responsible for leading a team of 12 employees and driving the company's growth initiatives.
Track Record: Under Michael F. O'Shea's leadership, Xcelerate Inc. has focused on acquiring and developing a portfolio of early-stage medical technologies. Key milestones include securing patents for innovative designs and establishing partnerships with clinical care settings for testing and validation. O'Shea has been instrumental in steering the company's strategic shift towards end-to-end medical technology development, positioning Xcelerate as a facilitator of healthcare innovation.
XCRT OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Xcelerate Inc. may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may be subject to less regulatory oversight compared to those listed on major exchanges like the NYSE or NASDAQ. Investing in OTC Other stocks involves higher risk due to the potential for limited information and price volatility.
- OTC Tier: OTC Other
- Limited Liquidity: Difficulty in buying or selling shares due to low trading volume.
- Information Scarcity: Lack of comprehensive financial disclosures and regulatory oversight.
- Price Volatility: Higher price fluctuations due to limited trading activity.
- Potential for Fraud: Increased risk of fraudulent activities due to less stringent listing requirements.
- Going Concern Risk: Uncertainty about the company's ability to continue operating due to financial challenges.
- Verify the company's legal standing and registration.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team's experience and track record.
- Check for any regulatory actions or legal disputes.
- Monitor trading volume and price volatility.
- Consult with a financial advisor before investing.
- Focus on medical technology development.
- Patents and intellectual property.
- CEO with relevant industry experience.
- End-to-end service offering.
- Partnerships with clinical care settings.
Xcelerate Inc. Healthcare Stock: Key Questions Answered
Is XCRT a good stock to buy?
Stock Expert AI does not rate XCRT buy, sell or hold. Xcelerate Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the XCRT stock price today?
The last price recorded on this page for Xcelerate Inc. (XCRT) is $0.01888, as of the Nov 19, 2026 trading session. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What do analysts say about XCRT stock?
Currently, there is no available analyst coverage or consensus on Xcelerate Inc. (XCRT) stock. Given the company's small market capitalization of $8.20M and OTC listing, it is not widely followed by major research firms.
What are the key factors to evaluate for XCRT?
Evaluate XCRT on fundamentals, analyst consensus, and risk factors. Xcelerate Inc. presents a high-risk, high-reward investment profile due to its focus on early-stage medical technologies. Not financial advice.
How frequently does XCRT data refresh on this page?
XCRT's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven XCRT's recent stock price performance?
Xcelerate Inc. (XCRT) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on early-stage medical technology development. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider XCRT overvalued or undervalued right now?
Xcelerate Inc. (XCRT) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research XCRT before investing?
Before investing in Xcelerate Inc. (XCRT), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Data provided for informational purposes only.
- Limited information available for OTC-traded companies.
- Financial data may not be fully up-to-date.